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Abstract 
Psychedelic drugs have long been known to be capable of inducing mystical or transcendental 
experiences, particularly at higher doses. However, given the common “recreational” nature of 
much present-day psychedelic drug use, with typical doses tending to be lower than those 
commonly taken in the 1960s, the extent to which illicit use of psychedelics today is associated 
with mystical experiences is not known. Furthermore the mild psychedelic stimulant MDMA 
(“ecstasy”) is more popular today than “full” psychedelics such as LSD or psilocybin, and the 
contribution of illicit MDMA use to mystical experiences is not known. The present study 
recruited 337 adults from the website and newsletter of the Multidisciplinary Association for 
Psychedelic Studies (MAPS), most of whom reported use of a variety of drugs both licit and 
illicit including psychedelics. Although only a quarter of the sample reported “spiritual” motives 
for using psychedelics, and such drugs were reportedly used only “rarely” by participants, 
psychedelic drug use (LSD and psilocybin) was significantly positively related to scores on two 
well-known indices of mystical experiences in a dose-related manner, whereas use of MDMA, 
cannabis, cocaine, opiates and alcohol was unrelated to mysticism scores. Further, only use of 
LSD, psilocybin or MDMA was significantly related to reports of ever having had an experience 
of an “overwhelming” nature. Results suggest that even in today’s context of “recreational” drug 
use, psychedelic drugs such as LSD and psilocybin, when taken at higher doses, continue to 
induce mystical experiences in many users. 
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When taken in sufficient doses the psychedelic drugs LSD and psilocybin have been 
widely reported to elicit mystical or transcendental religious/spiritual experiences (e.g., Bakalar 
1985; Griffiths et al., 2006; Harris, 2011; Hasler et al., 2004; Hofmann, 1983; Horgan, 2003; 
Leary, 1965; Maslow, 1964; Pahnke, 1963, 1969; Pahnke & Richards, 1966; Smith, 2000; Watts, 
1965). Insights into God or Ultimate Reality, transcendence of the personal ego, merging with 
the cosmos and undergoing transformative death and rebirth are common elements of the 
mystical experiences reported by many of those who have taken high doses of LSD or 
psilocybin. Such reports resemble in some respects the classical descriptions of self-realization 
or enlightenment arising from the mystical traditions of major religions such as Buddhism and 
Hinduism (Grinspoon & Bakalar, 1979; Horgan, 2003; James, 1905; Suzuki, 1957; Watts, 1965).  
Psychedelic drugs are potent direct serotonin agonists (Jacobs, 1987) that can induce 
powerful activation of the cerebral cortex, especially the prefrontal region (Vollenweider et al., 
1997). Although the peak in popularity of psychedelics, particularly LSD, was in the 1960s, 
psychedelic drugs are still taken illicitly today but the purposes of present-day use can be quite 
different from the motives of typical LSD users in the 1960s. Today psychedelics are often used 
to enhance sensory experiences at concerts and dance parties - in contrast to the ego-transcending 
or “mind-expanding” goals of most psychedelics users in the 1960s. This change is reflected in 
the typical unit doses of LSD available on the black market today, which are considerably lower 
than the typical unit doses available in the 1960s (Laing & Siegel, 2003). Black market unit 
samples of LSD in both the U.S. and Europe in the 1960s often contained several hundred 
micrograms (erowid.org/chemicals/lsd/lsd_history1.shtml), a dose range characterized as 
“strong” or “heavy” by the popular drug use information website erowid.org; by contrast in the 
past decade typical black market LSD unit doses averaged only about 50 micrograms (Hidalgo, 
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2009; Laing & Siegel, 2003), a dose range characterized by erowid.org as “light” and said to be 
well below the threshold for a revelatory mystical psychedelic experience (Stafford, 1983).  
Moreover the most commonly used drug with psychedelic properties today is not LSD or 
psilocybin but MDMA (“ecstasy”), which induces a mix of stimulant and mild psychedelic 
effects that are reported to be less intense and more controllable than those induced by “full” 
psychedelics such as LSD and psilocybin (Rushkoff, 2001). LSD and psilocybin are often 
referred to as “entheogens,” meaning “to awaken God within,” whereas MDMA is often 
described as an “entactogen,” meaning “to touch within” (Bravo, 2001; Smith, 2000), reflecting 
the differences between MDMA and “full” psychedelics.  
 Pahnke (1963) and Griffiths et al. (2006) demonstrated that a strong dose of psilocybin 
administered in a controlled, supportive experimental setting can induce profound mystical 
experiences in drug-naïve subjects, with self-reported transformative effects for some that lasted 
decades (Doblin, 1991). The present study examined mystical experiences in relation to illicit 
drug use among a sample of “recreational” psychedelic and other drug users. Given that 
psychedelic drug dose is said to be a crucial factor influencing whether an occasion of use is 
capable of catalyzing a transformational mystical experience, we expected to find that the usual 
dosage taken as reported by users for the full psychedelics LSD and psilocybin, but not MDMA 
or non-psychedelic drugs such as cannabis, cocaine, opiates or alcohol, would  be positively 
related to self-reported mystical experiences as well as to experiences of an “overwhelming” 
nature. Scores on the Depression Anxiety and Stress Scales (DASS-21) served as a control for 
the potential influence of mild psychopathology on such self-reports. In addition, self-report 
measures of specific life values and empathy were examined as a previous cross-cultural study 
found that psychedelic drug users rated the life values of spirituality, creativity, concern for the 
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environment and concern for others more highly than did non-users (Lerner & Lyvers, 2006), a 
difference which the authors speculated might be a result of mystical experiences in the former 
group. Mindfulness was also examined given the foundation of that concept in the mystical Zen 
Buddhist tradition (e.g., Maezumi & Glassman, 2007).  
Method 
Participants 
 Participants were recruited online from members of the Multidisciplinary Association for 
Psychedelic Studies (MAPS) and those who visited its website (www.maps.org). MAPS is a 
nonprofit organization promoting research on potential medical and psychiatric applications of 
marijuana and psychedelic drugs. A monthly newsletter emailed to MAPS members contained a 
brief description of the online survey and a link to it. This information was also placed on the 
MAPS website. The total number of participants who completed the survey was 350, with 337 
providing usable data. Among these 337 participants, ages ranged from 16 to 79 years (M = 
29.12 years, SD = 12.14), and 68.5% were male. The majority (68%) reported having a 
university degree; 32% of participants were students, and 58% of participants were employed 
full-time.  
 Approval was obtained from the Bond University Human Research Ethics Committee 
prior to the commencement of the study. No incentive was offered for participation.  
Materials 
 To commence the online survey administered via Survey Monkey, each participant had to 
read an explanatory statement which assured them of the anonymity of their data, and informed 
them of their right to withdraw from the study at any time without consequence.  The following 
questionnaires comprised the survey. 
6 
 
This is an Accepted Manuscript version of the following article: 
Lyvers, M., & Meester, M. (2012). Illicit use of LSD or Psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a 
dose-dependent manner. Journal of Psychoactive Drugs, 44(5), 410-417. https://doi.org/10.1080/02791072.2012.736842 
It is deposited under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits non-commercial re-use, 
distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. 
Demographics and drug use questionnaire. This measure was created for this study and 
asked for the participants’ age, gender, education, occupation, and personal history of use of 
alcohol and illegal drugs including cannabis (marijuana), MDMA (ecstasy), cocaine, opiates, 
LSD and psilocybin. Participants were asked to estimate their frequency of use on a six-point 
scale where 0 = “never,” 1 = “daily,” 2 = “weekly,” 3 = “fortnightly,’ 4 = “monthly’ and 5 = 
“rarely.” They were also asked to estimate their usual dosage taken on a four-point scale where 0 
= “none,” 1 = “low dose,” 2 = “common dose,” and  3 = “strong dose.”. Participants were also 
asked if they had ever had an overwhelmingly intense experience of any kind - not necessarily 
drug induced but could include drug experiences – by ticking either “yes” or “no.” For those who 
indicated they had used psychedelics, a question asked for the participant’s motives for such use. 
 Mysticism Scale (Hood, 1975). This 32-item questionnaire contains items that ask 
participants about past mystical experiences (if any). The Mysticism Scale has been used in 
research on the psychology of religion (Spilka, Hood, Hunsberger & Gorsuch,  2005) but has 
only previously been applied to drug experiences by Griffiths et al. (2006), who used it to 
assess psychedelic drug (psilocybin) experiences. The Mysticism Scale yields a total score 
based on three dimensions of mystical experience: noetic quality (e.g., “I have never 
experienced anything to be divine,” reverse-scored); introvertive mysticism (e.g., “I have 
never had an experience which I was unable to express adequately through language,” 
reverse-scored); and extrovertive mysticism (e.g, “I have had an experience in which I felt 
everything in the world to be part of the same whole”). The items are rated on a nine-point 
scale ranging from −4  = “this description is extremely not true of my own experience or 
experiences” through 0 = “I cannot decide” to +4 = “this description is extremely true of my 
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own experience or experiences.” The psychometric properties of this scale have been 
reported to be sound (Reinert & Steifler, 1993).  
 States of Consciousness Questionnaire (SCQ; Griffiths et al., 2006). The SCQ contains 
100 items pertaining to states of consciousness and mood, but only the 43 items of the Pahnke-
Richards Mystical Experience Questionnaire (MEQ; Pahnke, 1969; Richards, 1975) are 
scored, with the remainder being distractor items. The MEQ was used in Pahnke’s 1966 
Good Friday experiment as well as in the subsequent psilocybin study by Griffiths et al. (2006), 
the latter in the form of the SCQ as in the present study. The MEQ assesses experiences of 
internal unity, external unity, transcendence of time and space, ineffability, paradoxicality, 
sacredness, noetic quality, and positive mood. Participants rated each statement on a six-point 
Likert scale for degree of having experienced the phenomenon listed, from 0 = “not at all” to 5 = 
“extreme.” A sample item is “sense of profound humility before the majesty of what was felt to 
be sacred or holy.” Total scores can range from 0 to 215. 
 Balanced Emotional Empathy Scale (BEES; Mehrabian, 1996). This scale assesses 
one’s perceived ability to identify and feel the emotions of others. Participants rate 30 items on a 
nine-point Likert scale where -4 = “very strong disagreement,” 0 = “neither agreement or 
disagreement,” and +4 = “very strong agreement” with each item. A sample item is “I am moved 
deeply when I observe strangers who are struggling to survive.” Research has indicated that the 
BEES has good to excellent internal consistency, convergent validity and predictive validity 
(Mehrabian & Epstein, 1972; Mehrabian, Young & Sato, 1988).  
 Life Values Inventory (LVI; Crace & Brown, 1996). The LVI uses 42 items to measure 
14 different life values that are rated for personal importance on a five-point Likert scale, where 
1 = “almost never guides my behavior,” 3 = “sometimes guides my behavior” and 5 = “almost 
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always guides my behavior.” The 14 life values are achievement, belonging, concern for the 
environment, concern for others, creativity, financial prosperity, health and activity, humility, 
independence, loyalty to family or group, privacy, responsibility, scientific understanding, and 
spirituality. Brown and Crace reported high test-retest reliability for the 14 life values ranging 
from .78 to .97. For the purpose of this study only creativity, spirituality, concern for the 
environment, and concern for others were examined, based on previous findings described earlier 
above (Lerner & Lyvers, 2006).  
 Langer Mindfulness Scale (LMS; Langer, 2004). The LMS assesses the construct of 
mindfulness as practiced in everyday life. Participants rate 21 items in reference to their personal 
outlook on a five-point Likert scale where 1 = “strongly disagree,” 3 = “neutral,” and 5 = 
“strongly agree.” There are four subscales, novelty-seeking, engagement, novelty-producing, and 
flexibility; as these have been found to load onto a single scale score, only the total score was 
used in the present study.  
Depression Anxiety and Stress Scales (DASS-21; Lovibond & Lovibond, 1995). The  
DASS-21 is comprised of 21 items concerning negative mood states experienced in the past 
week, rated using a four point Likert rating scale where 0 = “these statements did not apply to me 
at all,” 1 = “applied to me some of the time,” 2 = “applied to me a good part of the time,” and 3 = 
“applied to me most of the time.” There are three subscales, Depression, Anxiety and Stress. 
Items include “I just couldn’t seem to get going” (Depression), “I found it difficult to relax” 
(Anxiety) and “I found it hard to wind down” (Stress). Normal scores for Depression are 0-9, 
Anxiety 0-7, and Stress 0-14 (Lovibond & Lovibond, 1995), with higher scores indicating 
psychopathology. The psychometric properties of this widely used measure are regarded as 
excellent (Crawford & Henry, 2003).  
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Procedure 
 Participants completed the questionnaires anonymously online via Survey Monkey. Once  
participants opened the link to the present survey on the computer that he or she used, they first 
read the explanatory statement . Then, participants clicked “Next,” which directed them to the 
demographics questionnaire. After the completion of this section, participants proceeded to the 
other questionnaires. Upon completing the last questionnaire, participants clicked “Finished,” 
which brought them to a thank you and appreciation page.  
Results 
 After removal of multivariate outliers and cases with substantial missing data from the 
dataset, 337 cases remained to provide usable data. Of these 337 participants, 99% reported 
having used alcohol, 58% reported having used cocaine, 40% reported having used opiates, 96% 
reported having used cannabis, 74% reported having used MDMA, 83% reported having used 
LSD, and 89% reported having used psilocybin. The very high proportions of the sample who 
reported having used cannabis and psychedelics was expected given the nature of MAPS as an 
advocacy group promoting potential beneficial applications of these substances. However, 
estimated self-reported frequency of drug use was low in this sample except for use of alcohol 
and cannabis. The most commonly reported frequency of use for alcohol was “weekly” (35%), 
whereas for cannabis the most commonly reported frequency of use was “daily” (44%). By 
contrast, “rarely” (less than monthly) was the most commonly reported frequency of use for 
cocaine, opiates, MDMA, LSD and psilocybin in this sample. Self-reported doses taken showed 
a broader distribution than frequency of use, although “common” was the most frequently cited 
dose level with frequencies ranging from 13% to 45% for this dose category; the exceptions were 
cocaine and opiates, for which the most commonly cited quantity was “none” (these drugs 
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having the lowest proportion of users in the sample; see above). DASS Depression, Anxiety and 
Stress scores were quite low in this sample, averaging only 3-4 out of a possible 21. Among 
those who reported having used psychedelics and provided motives for use, the most common 
self-reported motive for use was “mind expansion” (41%), followed by “spiritual” (25%), 
“curiosity” (13%) and “recreation” (7%), with the remainder citing “other.”  
 Intercorrelations among the measures of interest were calculated and are presented in 
Table 1. Illicit drug doses were all intercorrelated as expected, such that self-reported use of 
higher doses of any one drug were associated with self-reported use of higher doses of other 
drugs as well. LSD dose was significantly positively correlated with scores on the Mysticism 
Scale, MEQ, and LVI Creativity. Psilocybin dose was significantly positively correlated with 
Mysticism and MEQ scores. The other illicit drugs (cocaine, cannabis, opiates, MDMA) showed 
only small to no correlation with any of the scales, and none with Mysticism or MEQ scores. 
Alcohol dose was significantly negatively correlated with BEES empathy scores and three of the 
five LVI values, environmental concern, concern for others, and spirituality. Participant age was 
significantly negatively related to all self-reported drug doses except cocaine, and significantly 
positively related to BEES empathy, LVI environmental concern and LVI spirituality.  
Several of the scales were significantly intercorrelated in expected ways. For example, 
BEES empathy scores were positively correlated with LVI concern for others; LVI spirituality 
scores and LMS mindfulness were positively correlated with each other and with Mysticism, 
MEQ, BEES, and LVI concern for others, creativity and environmental concern; and the DASS 
scales were all intercorrelated as usual (e.g., Lyvers et al., 2009) although interestingly they did 
not significantly correlate with any other measure including drug use indices (see Table 1).  
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 Hierarchical regression was used to assess predictors of the primary criterion measures of 
interest, i.e., Mysticism Scale scores and MEQ scores, examining the possible roles of LSD and 
psilocybin dose after controlling for demographic variables, mood variables, and self-reported 
doses of drugs other than LSD or psilocybin. In these regressions age, gender and education level 
were entered at step 1, followed by DASS Depression, Anxiety and Stress scores at step 2, self-
reported doses of alcohol, cannabis, cocaine, opiates and MDMA at step 3, and self-reported 
doses of LSD and psilocybin at step 4. For prediction of Mysticism Scale scores the regression 
model was only significant at step 4, F(13, 291) = 2.79, p < .001; the addition of psychedelic 
drugs at step 4 accounted for 11% of the variance in Mysticism Scale scores, Fchange(2, 291) = 
10.60, p < .0001. The only significant drug predictors of Mysticism scale scores were LSD dose, 
β = .23, p < .0001, and psilocybin dose, β = .13, p = .04. No other predictors approached 
significance except for age at step 4 only, β = .14, p = .02. For MEQ scores as the criterion the 
results were very similar; again the regression model was only significant at step 4, F(13, 291) = 
3.12, p < .0001, and the addition of psychedelic drugs at step 4 explained 12% of the variance in 
MEQ scores, Fchange(2, 291) = 12.60, p < .0001. The only significant drug predictor in the final 
model was LSD dose, β = .26, p < .0001, with psilocybin dose approaching significance, β = .11, 
p = .07, and age again significant at step 4 only, β = .13, p = .03.  
 Finally, among drug use variables, only use of drugs with psychedelic properties was 
significantly related to the report of having ever had an overwhelming experience. Among those 
who reported ever using LSD (n = 280),  89% responded “yes” to the question asking whether 
they had ever had an overwhelmingly intense experience of any kind, compared to only 68% of 
those who said they never tried LSD (n = 56), a significant association, χ2(1) = 15.81, p < .0001. 
Similarly, among those who reported ever using psilocybin (n = 299), 88% reported having had 
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an overwhelming experience versus only 59% of those who said they had never tried psilocybin 
(n = 37), again a significant association, χ2(1) = 21.61, p < .0001. By contrast there was no 
relationship between use of the non-psychedelic drugs alcohol, cocaine, opiates, and cannabis 
with having ever had an overwhelming experience, all p > .20; however use of MDMA, a drug 
with mixed stimulant and mild psychedelic properties, was significantly related to the report of 
an overwhelming experience, χ2(1) = 14.96, p < .0001. Of those who said they had tried MDMA 
(n = 249), 85% reported having ever had an overwhelming experience compared to 72% of those 
who said they had never taken MDMA (n = 87). However, use of MDMA was strongly related to 
use of LSD, with 90% of those who reported ever using MDMA also reporting use of LSD 
versus only 61% of those who reported never using MDMA, χ2(1) = 41.00, p < .0001; nearly 
identical results were obtained for self-reported use of psilocybin by those who reported use of 
MDMA versus those who did not, χ2(1) = 28.67, p < .0001. Therefore the reports of 
overwhelming experiences by MDMA users may reflect their use of LSD or psilocybin rather 
than MDMA. In an attempt to assess this, MDMA use was examined in relation to reports of an 
overwhelming experience among the 15 participants who said they had never tried LSD or 
psilocybin, 10 of whom reported never using MDMA versus 5 who reported MDMA use. In this 
subgroup there was no significant association between MDMA use and reports of an 
overwhelming experience, χ2(1) = 1.25, p = .26, however given the very small size of this 
subgroup the lack of significance is not surprising. Of those who said they had used MDMA, 3 
out of 5 reported having ever had an overwhelming experience versus only 3 out of 10 of those 
who reported never using MDMA. By contrast among those 57 participants who reported never 
using LSD, psilocybin use was significantly related to reports of ever having had an 
overwhelming experience, p < .01; likewise among the 37 who reported never using psilocybin, 
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LSD use was significantly related to reports of ever having had an overwhelming experience, p < 
.05.  
Discussion 
 Results were in line with predictions for the two indices of mystical experiences, the 
Mysticism Scale and the MEQ, the variances of which were significantly explained by self-
reported dose of LSD or psilocybin but not of other drugs. Furthermore the self-report of having 
ever had an overwhelming experience was significantly associated only with self-reported use of 
drugs with psychedelic properties, i.e., LSD, psilocybin and MDMA, although the latter 
association may reflect the extremely high overlap between MDMA users and users of the “full” 
psychedelics LSD or psilocybin in this sample. Mysticism Scale and MEQ scores were 
significantly highly positively correlated with each other and with all four LVI values 
(environmental concern, concern for others, creativity and spirituality) as well as with BEES 
empathy and LMS mindfulness, consistent with expectations based on the mystical traditions of 
Buddhism and other religions according to which such values, as well as mindfulness, can be 
lasting sequelae of mystical enlightenment. However, aside from a small positive correlation 
between self-reported LSD dose and LVI creativity, there were no significant relationships 
between self-reported dose of any illicit drug – including psychedelics - and the other LVI values 
tested, nor with BEES empathy or LMS mindfulness. Alcohol dose was negatively related to 
BEES empathy and LVI environmental concern, concern for others and spirituality.  
 The vast majority of the current sample of MAPS members and those who visited the 
MAPS website reported use of psychedelic drugs. This was expected based on the mission of 
MAPS, a nonprofit organization dedicated to supporting medical and psychiatric applications of 
psychedelic drugs as well as MDMA and cannabis. However the vast majority reported only 
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“rare” (i.e., less than once per month) use of such drugs; 74% of LSD users said they “rarely” 
used LSD, 77% of psilocybin users said they “rarely” used psilocybin, and 69% of MDMA users 
said they “rarely” used MDMA. This was in contrast to cannabis users, 44% of whom reported 
“daily” use. Despite the low frequency of use of psychedelic drugs in the sample, self-reported 
psychedelic dose predicted scores on the two mystical experiences questionnaires as per 
expectations. The most commonly cited reason given for psychedelic drug use was “mind 
expansion,” although a quarter of psychedelic drug users cited “spiritual” reasons for use. 
Present findings indicate that, although the 1960s have long passed and black market LSD unit 
doses have dramatically declined, illicit use of psychedelic drugs LSD and psilocybin is still 
significantly associated with experiences that can be characterized as mystical, transcendental or 
spiritual in nature, a relationship which appears to be dose-dependent. Self-reported doses of the 
quasi-psychedelic drug MDMA, on the other hand, did not predict such experiences in this 
sample, nor did any other drug examined.  
 Although LSD and psilocybin have long been recognized as capable of inducing mystical 
experiences, Horgan (2003) suggested that, as yet, no “psychedelic saints” have emerged from 
the psychedelic user subculture. Horgan’s comment begs the question of how to determine 
“sainthood” outside of an established religious tradition such as Catholicism. Lerner and Lyvers 
(2006) found that users of psychedelics such as LSD or psilocybin differed from users of non-
psychedelic drugs such as cannabis in terms of higher empathy scores and higher scores on LVI 
creativity, spirituality, concern for others and concern for the environment in the former group. 
The authors speculated that such differences may in part have resulted from psychedelic mystical 
experiences in the former group. However, in the present study the strong positive relationships 
between self-reported dose of LSD or psilocybin and scores on the two mystical experience 
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questionnaires, coupled with the lack of relationships between psychedelic drug dose and scores 
on empathy, spirituality, concern for others and concern for the environment, suggest a different 
interpretation. For various reasons those who choose to use psychedelic drugs may on average 
place greater value on empathy, concern for the environment, creativity, and spirituality than 
those who do not choose to use psychedelics, as previously found by Lerner and Lyvers in both 
Israel and Australia, but the present results do not suggest that those differences specifically arise 
out of psychedelic-induced mystical experiences. Rather the group differences found by Lerner 
and Lyvers likely reflect the self-selected nature of psychedelic users and their associated 
subculture, which even today may share many of the values of the “hippie” movement of the 
1960s. In mystical religious traditions perhaps the posited relationship between non-drug-
induced spiritual enlightenment and “saintly” values –  exemplified by the Mahayana Buddhist 
ideal of the enlightened Bodhisattva as one dedicated to reducing the suffering of all sentient 
beings - may to a significant extent reflect the nature of the person who undertakes such a 
rigorous mystical quest through traditional means, typically requiring many years of highly 
demanding sacrifices and self-discipline in search of ultimate truth, rather than the transient 
mystical experience of enlightenment per se (Harris, 2011).  
 The present findings that higher self-reported doses of the psychedelic drugs LSD and 
psilocybin were associated with higher scores on two indices of mystical experiences should not 
be interpreted as encouraging psychedelic drug use, much less use of high doses. Although both 
LSD and psilocybin are physically very safe, the psychological hazards of uncontrolled use can 
be quite high, as was demonstrated in the 1960s when uncontrolled LSD use was widespread 
(e.g., Cohen, 1970). Panic reactions and “bad trips” followed by post-traumatic stress symptoms 
such as “flashbacks” were widely reported among casual users of psychedelic drugs in the 1960s, 
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although such reactions tend to be much rarer when the drugs are taken by psychologically 
stable, mature participants in a supportive, controlled environment - as in the recent study by 
Griffiths et al. (2006). Nevertheless even in the latter experiment about one third of participants 
reported “significant fear” (p. 15) during their psilocybin experience. Griffiths et al. noted that 
under uncontrolled conditions such reactions might easily lead to irrational behavior that could 
be dangerous to the user or to others. Given the unpredictability and intensity of psychedelic 
drug effects, such drugs should never be taken casually. Any future licit applications of such 
drugs are likely to be restricted to highly controlled circumstances involving careful screening, 
preparation and support of those who take these substances for a specific purpose, whether 
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Table 1 
Pearson correlations among self-reported dosage of drugs used and scores on questionnaires (see text for details). 
 
Variables     1       2        3         4        5        6         7          8         9      10       11        12      13      14     15     16     17     18     19 
 
1 Age        --    -.31**  -.05  -.12*    -.22**   -.20**   -.18**  -.21**   .15**   .08     .10      .08     .24**    .09    .04   .25**  -.04   -.06   -.02 
2 Alcohol            --     .15**  .03      .17**    .20**    .12*     .13*   -.16**   -.09    -.05     -.02   -.16**  -.13*  -.09  -.18**    .01    .05    .06 
3 Cocaine    --     .28**    .18**    .40**    .20**    .23**   .08      .06     .05      .04     .03     .05     .05   .01      .03   -.10   .01    
4 Opiates               --     .18**    .19**    .17**   .18**    .03     .09     .10      .12*   -.02     .05     .05  -.06    -.03   -.03   .05 
5 Cannabis               --     .13*      .21**   .19**   -.07     .01     .04      .08    -.05   -.12*    .03    .03     .03    .07    .04 
6 MDMA     --      .38**    .34**   .00    . 02     .08      .07    -.04     .06    -.01  -.10     .04   -.01  -.03   
7 LSD                                        --      .35**    .01     .10     .23**   .26**   .07    .02     .16**  .00     .03    .08    .02 
8 Psilocybin                                                             --    -.01     .00     .19**   .19**   .05     .00     .00   -.07     .09    .06    .05 
9 BEES                 --     .35**   .30**   .27**  .25**  .50**   .18**   .27**  -.02   -.05  -.06    
10 LMS               --      .34**   .33**  .23*   .31**   .55**   .19**   .03   -.01   .05 
11 Mysticism Scale              --     .86**  .22**    19**   .25**   .40**  -.03   -.04  -.07 
12 MEQ                         --    .22**  .16**   .28**   .38**  -.05   -.05  -.08 
13 Environmental concern                   --     49**   .33**   .42** -.05   -.04  -.04 
14 Concern for others                             --     .30**    .35**   .02   -.08  -.08 
15 Creativity                             --     .23**   .05    .05   .03 
16 Spirituality                            --     .02   .  03  -.02 
17 Depression                  --       .42** .64** 
18 Anxiety                           --       .52** 
19 Stress                          -- 
 
Note: * p < .05.  ** p < .01.                   
22 
 
This is an Accepted Manuscript version of the following article: 
Lyvers, M., & Meester, M. (2012). Illicit use of LSD or Psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a 
dose-dependent manner. Journal of Psychoactive Drugs, 44(5), 410-417. https://doi.org/10.1080/02791072.2012.736842 
It is deposited under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits non-commercial re-use, 
distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. 
 
